portonpharma.comCrawled Nov 10, 2026
Porton offers CDMO services for proteins and conjugate drugs, covering process development and formulation production to support global pharmaceutical companies in product commercialization.
Porton focuses on digital transformation, emphasizing process digitization, smart manufacturing, and supply chain collaboration to deliver efficient pharmaceutical services.
Porton Pharmaceuticals’ Chemical Engineering and Technology Center offers multidisciplinary support for the development and production of active pharmaceutical ingredients.
Porton provides CDMO services for small molecule drugs, covering end-to-end solutions from active pharmaceutical ingredients to formulations with high quality and efficiency.
Porton Pharmaceuticals will exhibit its CDMO services at the 2023 Bio-Europe conference in Germany, engaging with global customers.
Porton Pharmaceuticals will attend the CPHI Worldwide Pharma Expo in Barcelona in October 2023, showcasing end-to-end CDMO services for small molecules, peptides, and proteins.
The page highlights Porton Pharmaceuticals’ latest updates on capacity expansion, strategic partnerships, and industry events to drive innovation and collaboration in the pharmaceutical sector.
The page explores Duchenne muscular dystrophy (DMD), a severe genetic disease affecting children, and Porton Pharmaceuticals’ commitment to raising awareness and research for rare diseases.
The management team at Porton Pharmaceuticals includes experts in production, operations, finance, and research and development, dedicated to delivering global solutions.
Botene’s governance structure includes an experienced leadership team with diverse expertise in production, operations, finance, and R&D, supporting global solutions for clients.
Porton J-STAR, founded in North America in 1996, operates as a key research and production hub with 12,000 square meters of space and a high proportion of PhD staff. It provides customized research and development services for small molecules and conjugate drugs across multiple fields, featuring two advanced research centers.
Porton Pharmaceuticals offers full lifecycle services from research to commercialization, focusing on small molecules, peptides, and gene therapies for global pharmaceutical companies.
The Chongqing Liangjiang formulation production base covers 52,000 square meters with five production lines, offering diverse dosage forms like tablets and injections. It provides end-to-end services from research to commercial production, adhering to quality standards.
Botene Pharmaceuticals outlines its commitments and actions in environmental, social, and governance (ESG) initiatives, including EHS policies, reports, and corporate responsibility efforts.
Porton connects stakeholders with experts for early access to small molecules, biologics, and advanced therapies.
The legal disclaimer page for Chongqing Porton Pharmaceutical Technology Co., Ltd. outlines terms of use, intellectual property, liability disclaimers, and applicable laws for website compliance.
Porton secures the **CDMO Leadership Award for Global Small Molecule API** in recognition of its expertise in contract development and manufacturing. The award highlights the company’s role in supporting pharmaceutical innovation through advanced small-molecule drug production. Porton serves as a key partner for biopharmaceutical firms seeking scalable API solutions.
Mar 2025CPHI OnlineNews article
